Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis
Background Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurren...
Saved in:
Published in: | Annals of surgical oncology Vol. 19; no. 2; pp. 402 - 408 |
---|---|
Main Authors: | , , , , , , , , |
Format: | Journal Article |
Language: | English |
Published: |
New York
Springer-Verlag
01-02-2012
Springer Nature B.V |
Subjects: | |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Abstract | Background
Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery.
Methods
We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model.
Results
Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9–3.7,
P
< 0.0001; and hazard ratio 2.1, 95% CI 1.4–3.2,
P
< 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9–3.6,
P
< 0.0001), indicating that this biomarker can independently predict the survival of these patients.
Conclusions
CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments. |
---|---|
AbstractList | Background
Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery.
Methods
We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model.
Results
Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9–3.7,
P
< 0.0001; and hazard ratio 2.1, 95% CI 1.4–3.2,
P
< 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9–3.6,
P
< 0.0001), indicating that this biomarker can independently predict the survival of these patients.
Conclusions
CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments. Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery. We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model. Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9-3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4-3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9-3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients. CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments. BACKGROUNDAlthough surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery.METHODSWe considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model.RESULTSUnivariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9-3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4-3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9-3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients.CONCLUSIONSCD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments. Background: Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery. Methods: We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model. Results: Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9-3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4-3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9-3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients. Conclusions: CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments. Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested the hypothesis that the detection of circulating tumor cells (CTC) might identify patients at high risk of dying of disease recurrence after apparently radical liver surgery. We considered 50 patients undergoing radical surgery for liver-confined hepatic metastasis from CRC. The expression of a panel of cancer-related genes, as assessed by quantitative real-time PCR, was used to detect CTC in the peripheral blood of these patients immediately before surgery. Survival analysis was performed by the Cox regression model. Univariate analysis of the expression levels of CD133 (a marker of colon cancer stem cells) and survivin (an antiapoptotic factor) resulted in statistically significant association with patient survival [hazard ratio (HR) 2.7, 95% confidence interval (CI) 1.9-3.7, P < 0.0001; and hazard ratio 2.1, 95% CI 1.4-3.2, P < 0.0001, respectively]. Remarkably, multivariate analysis found that only the transcriptional amount of CD133 resulted in statistical significance (HR 2.6, 95% CI 1.9-3.6, P < 0.0001), indicating that this biomarker can independently predict the survival of these patients. CD133-positive CTC may represent a suitable prognostic marker to stratify the risk of patients who undergo liver resection for CRC metastasis, which opens the avenue to identifying and potentially monitoring the patients who are most likely to benefit from adjuvant treatments.[PUBLICATION ABSTRACT] |
Author | Bertazza, Loris Pilati, Pierluigi Briarava, Marta Mocellin, Simone Galdi, Francesca Mammano, Enzo Zavagno, Giorgio Nitti, Donato Tessari, Emanuela |
Author_xml | – sequence: 1 givenname: Pierluigi surname: Pilati fullname: Pilati, Pierluigi organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 2 givenname: Simone surname: Mocellin fullname: Mocellin, Simone email: simone.mocellin@unipd.it organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 3 givenname: Loris surname: Bertazza fullname: Bertazza, Loris organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova, Istituto Oncologico Veneto (IOV-IRCCS) – sequence: 4 givenname: Francesca surname: Galdi fullname: Galdi, Francesca organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 5 givenname: Marta surname: Briarava fullname: Briarava, Marta organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 6 givenname: Enzo surname: Mammano fullname: Mammano, Enzo organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 7 givenname: Emanuela surname: Tessari fullname: Tessari, Emanuela organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 8 givenname: Giorgio surname: Zavagno fullname: Zavagno, Giorgio organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova – sequence: 9 givenname: Donato surname: Nitti fullname: Nitti, Donato organization: Surgery Branch, Department of Oncological and Surgical Sciences, University of Padova |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/22071867$$D View this record in MEDLINE/PubMed |
BookMark | eNp9kUuLFDEUhYPM4Dz0B7iR4EY3NeZVeSylUEfowUYdtyGVutXUUJ20SUpw7R83RY8KwgiB3OR-54Sbc4FOQgyA0DNKrigT7etMieCiIZQ2jHLWsEfonLb1RkhNT2pNpG4Mk-0Zusj5jhCqOGkfozPGiKJaqnP0c5viLsRcJo-_unkBHEe8XYor03fA3ZT8Mtc67HDngoeEPxfY4w7mOeMp4G3tQSgZ34YB0i6u4DUc3Gr3CTL4MsWAx5hwF-eY6tnNeFOtE76B4nJdU36CTkc3Z3h6v1-i23dvv3TXzebj-w_dm03jhTSl4d4QqaTRsh-JEsLrUZmejNyB7w0Bz9vRiUHzwQ-cC9F6CtpR3msnVNXxS_Ty6HtI8dsCudj9lH0dxQWIS7aGKt1qQWQlX_2XpKr-sDJGreiLf9C7uKRQ51j9ONVUthWiR8inmHOC0R7StHfph6XErlHaY5S2RmnXKC2rmuf3xku_h-GP4nd2FWBHINdW2EH6-_LDrr8A4sCrjw |
CitedBy_id | crossref_primary_10_1007_s10544_013_9775_7 crossref_primary_10_3109_09553002_2014_920968 crossref_primary_10_1007_s10616_012_9511_9 crossref_primary_10_4174_astr_2014_87_5_232 crossref_primary_10_1016_j_msec_2013_09_009 crossref_primary_10_1517_14728222_2012_667404 crossref_primary_10_1016_j_canlet_2013_12_019 crossref_primary_10_1074_jbc_M115_652628 crossref_primary_10_3390_ijms242417398 crossref_primary_10_3390_ijms13044367 crossref_primary_10_1186_s12957_022_02775_z crossref_primary_10_1016_j_molonc_2016_01_011 crossref_primary_10_1111_cas_15255 crossref_primary_10_1186_s12957_016_0793_9 crossref_primary_10_1016_j_canlet_2012_04_006 crossref_primary_10_1111_cpr_12175 crossref_primary_10_1371_journal_pone_0134948 crossref_primary_10_1186_1471_2407_14_511 crossref_primary_10_1007_s11888_013_0193_2 crossref_primary_10_1038_jid_2015_127 crossref_primary_10_2174_0113816128291321240329050945 crossref_primary_10_3109_09553002_2014_886798 crossref_primary_10_1186_s13059_014_0448_5 crossref_primary_10_1002_cyto_a_22206 crossref_primary_10_1002_path_4086 crossref_primary_10_1002_jcp_24145 crossref_primary_10_1016_j_gendis_2023_01_013 crossref_primary_10_1245_s10434_022_11973_8 crossref_primary_10_3748_wjg_v22_i46_10232 crossref_primary_10_1093_annonc_mdu018 crossref_primary_10_9738_INTSURG_D_16_00022_1 crossref_primary_10_1016_j_ctrv_2012_12_007 crossref_primary_10_3748_wjg_v20_i35_12458 crossref_primary_10_3390_gidisord1040030 crossref_primary_10_1016_j_ejso_2015_12_008 crossref_primary_10_2478_pjvs_2013_0022 crossref_primary_10_1136_jclinpath_2014_202499 crossref_primary_10_2147_OTT_S288191 crossref_primary_10_1245_s10434_014_3549_1 crossref_primary_10_3390_cells11192973 crossref_primary_10_1186_1477_7819_11_159 crossref_primary_10_1245_s10434_015_5038_6 crossref_primary_10_1016_j_ymeth_2012_10_003 crossref_primary_10_1177_11795549221126249 crossref_primary_10_1155_2019_3905817 crossref_primary_10_1186_s40792_018_0518_0 crossref_primary_10_1007_s11888_014_0251_4 crossref_primary_10_3892_mco_2013_116 crossref_primary_10_1007_s11888_012_0123_8 crossref_primary_10_3390_cancers16081556 crossref_primary_10_17795_ijcp_5897 crossref_primary_10_1016_j_procbio_2022_02_006 crossref_primary_10_1245_s10434_011_2135_z crossref_primary_10_3389_fonc_2022_947479 crossref_primary_10_1007_s13277_015_3132_9 crossref_primary_10_1016_j_clcc_2017_01_011 crossref_primary_10_3892_or_2014_3245 |
Cites_doi | 10.1111/j.1582-4934.2010.01117.x 10.1016/j.ejca.2009.11.003 10.1006/meth.2001.1262 10.1016/j.molmed.2010.07.001 10.1016/S0065-230X(08)60811-8 10.1002/cncr.22774 10.3816/CCC.2001.n.016 10.1007/s11888-010-0069-7 10.1634/theoncologist.2009-0094 10.1038/sj.bjc.6605762 10.1083/jcb.201010021 10.1586/egh.09.8 10.1002/ijc.20347 10.1038/nature05384 10.1111/j.1749-6632.2010.05779.x 10.1016/j.ctrv.2009.08.005 10.1097/00000658-199909000-00004 10.1016/S0140-6736(02)08272-7 10.1186/1479-5876-7-111 10.1159/000318862 10.1038/nrc2645 10.1097/CCO.0b013e32833a6c8a 10.2741/1761 10.1038/sj.bjc.6605651 10.1038/sj.bjc.6604664 10.1016/j.molmed.2005.05.002 10.1002/sim.2787 10.1053/j.gastro.2009.12.063 10.1016/j.molmed.2006.01.006 10.1016/0197-2456(96)00075-X 10.1038/nrgastro.2010.211 10.1038/sj.bjc.6605659 10.1200/JCO.2009.26.9340 10.1053/j.gastro.2010.01.008 10.1038/nature05372 10.1158/1078-0432.CCR-06-0823 10.1002/14651858.CD003770.pub3 10.1371/journal.pone.0012517 10.6004/jnccn.2011.0004 |
ContentType | Journal Article |
Copyright | Society of Surgical Oncology 2011 Society of Surgical Oncology 2012 |
Copyright_xml | – notice: Society of Surgical Oncology 2011 – notice: Society of Surgical Oncology 2012 |
DBID | CGR CUY CVF ECM EIF NPM AAYXX CITATION 3V. 7TO 7X7 7XB 88E 8AO 8FI 8FJ 8FK ABUWG AFKRA BENPR CCPQU FYUFA GHDGH H94 K9. M0S M1P PQEST PQQKQ PQUKI PRINS 7QO 8FD FR3 P64 7X8 |
DOI | 10.1245/s10434-011-2132-2 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef ProQuest Central (Corporate) Oncogenes and Growth Factors Abstracts ProQuest - Health & Medical Complete保健、医学与药学数据库 ProQuest Central (purchase pre-March 2016) Medical Database (Alumni Edition) ProQuest Pharma Collection Hospital Premium Collection Hospital Premium Collection (Alumni Edition) ProQuest Central (Alumni) (purchase pre-March 2016) ProQuest Central (Alumni) ProQuest Central ProQuest Central ProQuest One Community College Health Research Premium Collection Health Research Premium Collection (Alumni) AIDS and Cancer Research Abstracts ProQuest Health & Medical Complete (Alumni) Health & Medical Collection (Alumni Edition) PML(ProQuest Medical Library) ProQuest One Academic Eastern Edition (DO NOT USE) ProQuest One Academic ProQuest One Academic UKI Edition ProQuest Central China Biotechnology Research Abstracts Technology Research Database Engineering Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Oncogenes and Growth Factors Abstracts ProQuest One Academic Eastern Edition ProQuest Health & Medical Complete (Alumni) ProQuest Central (Alumni Edition) ProQuest One Community College ProQuest Hospital Collection Health Research Premium Collection (Alumni) ProQuest Pharma Collection ProQuest Central China ProQuest Hospital Collection (Alumni) ProQuest Central ProQuest Health & Medical Complete Health Research Premium Collection ProQuest Medical Library ProQuest One Academic UKI Edition Health and Medicine Complete (Alumni Edition) AIDS and Cancer Research Abstracts ProQuest One Academic ProQuest Medical Library (Alumni) ProQuest Central (Alumni) Engineering Research Database Biotechnology Research Abstracts Technology Research Database Biotechnology and BioEngineering Abstracts MEDLINE - Academic |
DatabaseTitleList | MEDLINE MEDLINE - Academic Engineering Research Database Oncogenes and Growth Factors Abstracts |
Database_xml | – sequence: 1 dbid: ECM name: MEDLINE url: https://search.ebscohost.com/login.aspx?direct=true&db=cmedm&site=ehost-live sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EISSN | 1534-4681 |
EndPage | 408 |
ExternalDocumentID | 2568194191 10_1245_s10434_011_2132_2 22071867 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -5E -5G -BR -EM -Y2 -~C .86 .VR 06C 06D 0R~ 0VY 199 1N0 1SB 203 23M 28- 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2WC 2~H 30V 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5VS 67Z 6J9 6NX 78A 7X7 88E 8AO 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATNV AATVU AAUYE AAWCG AAYFA AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFTV ABHLI ABHQN ABIPD ABJNI ABJOX ABKAS ABKCH ABKTR ABMNI ABMQK ABNWP ABOCM ABPLI ABQBU ABSXP ABTEG ABTKH ABTMW ABULA ABUWG ABUWZ ABWNU ABXPI ACBMV ACBRV ACBXY ACBYP ACGFO ACGFS ACHSB ACHVE ACHXU ACIGE ACIHN ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACREN ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADOXG ADRFC ADTPH ADURQ ADYFF ADYOE ADZKW AEAQA AEBTG AEEQQ AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESKC AESTI AETLH AEVLU AEVTX AEXYK AFAFS AFEXP AFJLC AFKRA AFLOW AFNRJ AFQWF AFWTZ AFYQB AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMTXH AMXSW AMYLF AMYQR AOCGG ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BAWUL BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI C1A CAG CCPQU COF CS3 CSCUP DDRTE DIK DL5 DNIVK DPUIP E3Z EBD EBLON EBS EIOEI EJD EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GX1 GXS HEOXT HF~ HG5 HG6 HMCUK HMJXF HQYDN HRMNR HVGLF HZ~ I09 IH2 IHE IJ- IKXTQ IMOTQ IWAJR IXC IXD IXE IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH L7B LAS LLZTM M1P M4Y MA- N2Q N9A NB0 NDZJH NPVJJ NQJWS NU0 O9- O93 O9G O9I O9J OAM OVD OWW P19 P2P P9S PF0 PQQKQ PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RNI ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SCLPG SDE SDH SDM SHX SISQX SJYHP SMD SNE SNPRN SNX SOHCF SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TEORI TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 WOQ YFH YLTOR Z45 Z5O Z7U Z7V Z7W Z7X Z81 Z82 Z83 Z87 Z8O Z8V Z91 ZMTXR ZOVNA AACDK AAEOY AAJBT AASML AAYZH ABAKF ACAOD ACDTI ACZOJ AEFQL AEMSY AFBBN AGQEE AGRTI AIGIU AJOOF ALIPV CGR CUY CVF ECM EIF H13 NPM AAYXX CITATION 7TO 7XB 8FK H94 K9. PQEST PQUKI PRINS 7QO 8FD FR3 P64 7X8 |
ID | FETCH-LOGICAL-c469t-3c90676986bf0744c8f79b0f3aecb90ec35fa4d83dcd33445c1e8a13b8a477693 |
IEDL.DBID | AEJHL |
ISSN | 1068-9265 |
IngestDate | Thu Oct 24 23:38:39 EDT 2024 Fri Oct 25 01:57:03 EDT 2024 Thu Oct 10 16:07:06 EDT 2024 Thu Nov 21 21:39:06 EST 2024 Tue Oct 15 23:44:18 EDT 2024 Sat Dec 16 12:02:57 EST 2023 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Liver Metastasis Colorectal Liver Metastasis Epithelial Growth Factor Receptor Vascular Endothelium Growth Factor Circulate Tumor Cell |
Language | English |
LinkModel | DirectLink |
MergedId | FETCHMERGED-LOGICAL-c469t-3c90676986bf0744c8f79b0f3aecb90ec35fa4d83dcd33445c1e8a13b8a477693 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 22071867 |
PQID | 917318165 |
PQPubID | 32486 |
PageCount | 7 |
ParticipantIDs | proquest_miscellaneous_917858406 proquest_miscellaneous_1746879976 proquest_journals_917318165 crossref_primary_10_1245_s10434_011_2132_2 pubmed_primary_22071867 springer_journals_10_1245_s10434_011_2132_2 |
PublicationCentury | 2000 |
PublicationDate | 2012-02-01 |
PublicationDateYYYYMMDD | 2012-02-01 |
PublicationDate_xml | – month: 02 year: 2012 text: 2012-02-01 day: 01 |
PublicationDecade | 2010 |
PublicationPlace | New York |
PublicationPlace_xml | – name: New York – name: United States |
PublicationTitle | Annals of surgical oncology |
PublicationTitleAbbrev | Ann Surg Oncol |
PublicationTitleAlternate | Ann Surg Oncol |
PublicationYear | 2012 |
Publisher | Springer-Verlag Springer Nature B.V |
Publisher_xml | – name: Springer-Verlag – name: Springer Nature B.V |
References | Todaro, Francipane, Medema, Stassi (CR35) 2011; 138 Lin, Hassan, Li (CR42) 2007; 110 Kemeny (CR3) 2010; 22 Hebbar, Pruvot, Romano (CR25) 2009; 35 Power, Kemeny (CR5) 2010; 28 Riethdorf, Pantel (CR31) 2010; 1210 O’Brien, Pollett, Gallinger, Dick (CR33) 2007; 445 Gazzaniga, Gradilone, Petracca (CR41) 2011; 14 Lise, Mocellin, Pilati, Nitti (CR2) 2005; 10 Horst, Kriegl, Engel (CR39) 2008; 99 Allen, El-Deiry (CR12) 2010; 6 Mocellin, Del Fiore, Guarnieri (CR19) 2004; 111 Weiss (CR28) 1990; 54 Primrose (CR1) 2010; 102 Grambsch, Therneau (CR21) 2000 Dotan, Cohen, Alpaugh, Meropol (CR14) 2009; 14 Mocellin, Hoon, Ambrosi (CR16) 2006; 12 Harel, Zhou (CR24) 2007; 26 Nakamura, Iinuma, Aoyagi (CR37) 2011; 78 Mocellin, Lise, Nitti (CR9) 2005; 11 Yu, Stott, Toner (CR29) 2010; 192 Mocellin, Keilholz, Rossi, Nitti (CR15) 2006; 12 Livak, Schmittgen (CR20) 2001; 25 Rahbari, Aigner, Thorlund (CR10) 2010; 138 Clark, Altman, De Stavola (CR23) 2002; 359 CR6 Bertazza, Mocellin, Marchet (CR18) 2009; 7 Shmelkov, Butler, Hooper (CR36) 2008; 118 Pantel, Alix-Panabieres (CR13) 2010; 16 Artells, Moreno, Diaz (CR38) 2011; 46 CR26 Zeki, Graham, Wright (CR34) 2011; 8 Ruo, DeMatteo, Blumgart (CR7) 2001; 1 Walther, Johnstone, Swanton (CR27) 2009; 9 Lugli, Iezzi, Hostettler (CR40) 2011; 103 Fong, Fortner, Sun (CR17) 1999; 230 Ricci-Vitiani, Lombardi, Pilozzi (CR32) 2007; 445 Punnoose, Atwal, Spoerke (CR30) 2011; 5 Kelley, Van Bebber, Phillips, Venook (CR8) 2010; 9 Mayo, Pawlik (CR4) 2009; 3 Peach, Kim, Zacharakis (CR11) 2010; 102 Schemper, Smith (CR22) 1996; 17 22094495 - Ann Surg Oncol. 2012 Feb;19(2):351-2 N Kemeny (2132_CR3) 2010; 22 S Mocellin (2132_CR15) 2006; 12 DG Power (2132_CR5) 2010; 28 2132_CR6 RK Kelley (2132_CR8) 2010; 9 L Ruo (2132_CR7) 2001; 1 P Gazzaniga (2132_CR41) 2011; 14 2132_CR30 M Yu (2132_CR29) 2010; 192 K Nakamura (2132_CR37) 2011; 78 NN Rahbari (2132_CR10) 2010; 138 EH Lin (2132_CR42) 2007; 110 G Peach (2132_CR11) 2010; 102 S Mocellin (2132_CR9) 2005; 11 R Artells (2132_CR38) 2011; 46 JE Allen (2132_CR12) 2010; 6 S Mocellin (2132_CR19) 2004; 111 L Bertazza (2132_CR18) 2009; 7 TM Grambsch (2132_CR21) 2000 SV Shmelkov (2132_CR36) 2008; 118 M Schemper (2132_CR22) 1996; 17 TG Clark (2132_CR23) 2002; 359 M Lise (2132_CR2) 2005; 10 SC Mayo (2132_CR4) 2009; 3 L Ricci-Vitiani (2132_CR32) 2007; 445 S Mocellin (2132_CR16) 2006; 12 L Weiss (2132_CR28) 1990; 54 M Hebbar (2132_CR25) 2009; 35 O Harel (2132_CR24) 2007; 26 M Todaro (2132_CR35) 2011; 138 D Horst (2132_CR39) 2008; 99 A Lugli (2132_CR40) 2011; 103 KJ Livak (2132_CR20) 2001; 25 A Walther (2132_CR27) 2009; 9 JN Primrose (2132_CR1) 2010; 102 SS Zeki (2132_CR34) 2011; 8 2132_CR26 S Riethdorf (2132_CR31) 2010; 1210 K Pantel (2132_CR13) 2010; 16 E Dotan (2132_CR14) 2009; 14 Y Fong (2132_CR17) 1999; 230 CA O’Brien (2132_CR33) 2007; 445 |
References_xml | – volume: 14 start-page: 2073 year: 2011 end-page: 2077 ident: CR41 article-title: Molecular markers in circulating tumour cells from metastatic colorectal cancer patients publication-title: J Cell Mol Med. doi: 10.1111/j.1582-4934.2010.01117.x contributor: fullname: Petracca – volume: 46 start-page: 642 year: 2011 end-page: 649 ident: CR38 article-title: Tumour CD133 mRNA expression and clinical outcome in surgically resected colorectal cancer patients publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2009.11.003 contributor: fullname: Diaz – volume: 5 start-page: 12517 year: 2011 ident: CR30 article-title: Molecular biomarker analyses using circulating tumor cells publication-title: PLoS One. contributor: fullname: Spoerke – volume: 25 start-page: 402 year: 2001 end-page: 408 ident: CR20 article-title: Analysis of relative gene expression data using real-time quantitative PCR and the 2(−delta delta C(T)) method publication-title: Methods. doi: 10.1006/meth.2001.1262 contributor: fullname: Schmittgen – volume: 16 start-page: 398 year: 2010 end-page: 406 ident: CR13 article-title: Circulating tumour cells in cancer patients: challenges and perspectives publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2010.07.001 contributor: fullname: Alix-Panabieres – volume: 54 start-page: 159 year: 1990 end-page: 211 ident: CR28 article-title: Metastatic inefficiency publication-title: Adv Cancer Res. doi: 10.1016/S0065-230X(08)60811-8 contributor: fullname: Weiss – volume: 110 start-page: 534 year: 2007 end-page: 542 ident: CR42 article-title: Elevated circulating endothelial progenitor marker CD133 messenger RNA levels predict colon cancer recurrence publication-title: Cancer. doi: 10.1002/cncr.22774 contributor: fullname: Li – volume: 1 start-page: 154 year: 2001 end-page: 166 ident: CR7 article-title: The role of adjuvant therapy after liver resection for colorectal cancer metastases publication-title: Clin Colorectal Cancer. doi: 10.3816/CCC.2001.n.016 contributor: fullname: Blumgart – volume: 6 start-page: 212 year: 2010 end-page: 220 ident: CR12 article-title: Circulating tumor cells and colorectal cancer publication-title: Curr Colorectal Cancer Rep. doi: 10.1007/s11888-010-0069-7 contributor: fullname: El-Deiry – volume: 14 start-page: 1070 year: 2009 end-page: 1082 ident: CR14 article-title: Circulating tumor cells: evolving evidence and future challenges publication-title: Oncologist. doi: 10.1634/theoncologist.2009-0094 contributor: fullname: Meropol – volume: 103 start-page: 382 year: 2011 end-page: 390 ident: CR40 article-title: Prognostic impact of the expression of putative cancer stem cell markers CD133, CD166, CD44 s, EpCAM, and ALDH1 in colorectal cancer publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605762 contributor: fullname: Hostettler – volume: 192 start-page: 373 year: 2010 end-page: 382 ident: CR29 article-title: Circulating tumor cells: approaches to isolation and characterization publication-title: J Cell Biol. doi: 10.1083/jcb.201010021 contributor: fullname: Toner – volume: 3 start-page: 131 year: 2009 end-page: 144 ident: CR4 article-title: Current management of colorectal hepatic metastasis publication-title: Expert Rev Gastroenterol Hepatol. doi: 10.1586/egh.09.8 contributor: fullname: Pawlik – ident: CR6 – volume: 111 start-page: 741 year: 2004 end-page: 745 ident: CR19 article-title: Molecular detection of circulating tumor cells is an independent prognostic factor in patients with high-risk cutaneous melanoma publication-title: Int J Cancer. doi: 10.1002/ijc.20347 contributor: fullname: Guarnieri – volume: 9 start-page: 13 year: 2010 end-page: 25 ident: CR8 article-title: Personalized medicine and oncology practice guidelines: a case study of contemporary biomarkers in colorectal cancer publication-title: J Natl Compr Canc Netw. contributor: fullname: Venook – volume: 445 start-page: 111 issue: 7123 year: 2007 end-page: 115 ident: CR32 article-title: Identification and expansion of human colon-cancer-initiating cells publication-title: Nature doi: 10.1038/nature05384 contributor: fullname: Pilozzi – volume: 1210 start-page: 66 year: 2010 end-page: 77 ident: CR31 article-title: Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells publication-title: Ann N Y Acad Sci. doi: 10.1111/j.1749-6632.2010.05779.x contributor: fullname: Pantel – volume: 35 start-page: 668 year: 2009 end-page: 675 ident: CR25 article-title: Integration of neoadjuvant and adjuvant chemotherapy in patients with resectable liver metastases from colorectal cancer publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2009.08.005 contributor: fullname: Romano – volume: 230 start-page: 309 year: 1999 end-page: 318 ident: CR17 article-title: Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases publication-title: Ann Surg. doi: 10.1097/00000658-199909000-00004 contributor: fullname: Sun – volume: 359 start-page: 1309 issue: 9314 year: 2002 end-page: 1310 ident: CR23 article-title: Quantification of the completeness of follow-up publication-title: Lancet doi: 10.1016/S0140-6736(02)08272-7 contributor: fullname: De Stavola – volume: 7 start-page: 111 year: 2009 ident: CR18 article-title: Survivin gene levels in the peripheral blood of patients with gastric cancer independently predict survival publication-title: J Transl Med doi: 10.1186/1479-5876-7-111 contributor: fullname: Marchet – volume: 78 start-page: 309 year: 2011 end-page: 315 ident: CR37 article-title: Predictive value of cancer stem-like cells and cancer-associated genetic markers for peritoneal recurrence of colorectal cancer in patients after curative surgery publication-title: Oncology. doi: 10.1159/000318862 contributor: fullname: Aoyagi – year: 2000 ident: CR21 publication-title: Modelling survival data contributor: fullname: Therneau – volume: 9 start-page: 489 year: 2009 end-page: 499 ident: CR27 article-title: Genetic prognostic and predictive markers in colorectal cancer publication-title: Nat Rev Cancer. doi: 10.1038/nrc2645 contributor: fullname: Swanton – volume: 22 start-page: 364 year: 2010 end-page: 373 ident: CR3 article-title: The management of resectable and unresectable liver metastases from colorectal cancer publication-title: Curr Opin Oncol. doi: 10.1097/CCO.0b013e32833a6c8a contributor: fullname: Kemeny – volume: 10 start-page: 3042 year: 2005 end-page: 3057 ident: CR2 article-title: Colorectal liver metastasis: towards the integration of conventional and molecularly targeted therapeutic approaches publication-title: Front Biosci. doi: 10.2741/1761 contributor: fullname: Nitti – volume: 102 start-page: 1327 year: 2010 end-page: 1334 ident: CR11 article-title: Prognostic significance of circulating tumour cells following surgical resection of colorectal cancers: a systematic review publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605651 contributor: fullname: Zacharakis – volume: 99 start-page: 1285 year: 2008 end-page: 1289 ident: CR39 article-title: CD133 expression is an independent prognostic marker for low survival in colorectal cancer publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6604664 contributor: fullname: Engel – volume: 11 start-page: 327 year: 2005 end-page: 335 ident: CR9 article-title: Targeted therapy for colorectal cancer: mapping the way publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2005.05.002 contributor: fullname: Nitti – volume: 26 start-page: 3057 year: 2007 end-page: 3077 ident: CR24 article-title: Multiple imputation: review of theory, implementation and software publication-title: Stat Med. doi: 10.1002/sim.2787 contributor: fullname: Zhou – volume: 138 start-page: 2151 year: 2011 end-page: 2162 ident: CR35 article-title: Colon cancer stem cells: promise of targeted therapy publication-title: Gastroenterology. doi: 10.1053/j.gastro.2009.12.063 contributor: fullname: Stassi – volume: 12 start-page: 130 year: 2006 end-page: 139 ident: CR15 article-title: Circulating tumor cells: the “leukemic phase” of solid cancers publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2006.01.006 contributor: fullname: Nitti – volume: 17 start-page: 343 year: 1996 end-page: 346 ident: CR22 article-title: A note on quantifying follow-up in studies of failure time publication-title: Control Clin Trials. doi: 10.1016/0197-2456(96)00075-X contributor: fullname: Smith – volume: 118 start-page: 2111 year: 2008 end-page: 2120 ident: CR36 article-title: CD133 expression is not restricted to stem cells, and both CD133 and CD133 metastatic colon cancer cells initiate tumors publication-title: J Clin Invest. contributor: fullname: Hooper – ident: CR26 – volume: 8 start-page: 90 year: 2011 end-page: 100 ident: CR34 article-title: Stem cells and their implications for colorectal cancer publication-title: Nat Rev Gastroenterol Hepatol. doi: 10.1038/nrgastro.2010.211 contributor: fullname: Wright – volume: 102 start-page: 1313 year: 2010 end-page: 1318 ident: CR1 article-title: Surgery for colorectal liver metastases publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605659 contributor: fullname: Primrose – volume: 28 start-page: 2300 year: 2010 end-page: 2309 ident: CR5 article-title: Role of adjuvant therapy after resection of colorectal cancer liver metastases publication-title: J Clin Oncol. doi: 10.1200/JCO.2009.26.9340 contributor: fullname: Kemeny – volume: 138 start-page: 1714 year: 2010 end-page: 1726 ident: CR10 article-title: Meta-analysis shows that detection of circulating tumor cells indicates poor prognosis in patients with colorectal cancer publication-title: Gastroenterology. doi: 10.1053/j.gastro.2010.01.008 contributor: fullname: Thorlund – volume: 445 start-page: 106 issue: 7123 year: 2007 end-page: 110 ident: CR33 article-title: A human colon cancer cell capable of initiating tumour growth in immunodeficient mice publication-title: Nature doi: 10.1038/nature05372 contributor: fullname: Dick – volume: 12 start-page: 4605 year: 2006 end-page: 4613 ident: CR16 article-title: The prognostic value of circulating tumor cells in patients with melanoma: a systematic review and meta-analysis publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-06-0823 contributor: fullname: Ambrosi – volume: 54 start-page: 159 year: 1990 ident: 2132_CR28 publication-title: Adv Cancer Res. doi: 10.1016/S0065-230X(08)60811-8 contributor: fullname: L Weiss – volume: 445 start-page: 106 issue: 7123 year: 2007 ident: 2132_CR33 publication-title: Nature doi: 10.1038/nature05372 contributor: fullname: CA O’Brien – volume: 103 start-page: 382 year: 2011 ident: 2132_CR40 publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605762 contributor: fullname: A Lugli – volume: 6 start-page: 212 year: 2010 ident: 2132_CR12 publication-title: Curr Colorectal Cancer Rep. doi: 10.1007/s11888-010-0069-7 contributor: fullname: JE Allen – volume: 1 start-page: 154 year: 2001 ident: 2132_CR7 publication-title: Clin Colorectal Cancer. doi: 10.3816/CCC.2001.n.016 contributor: fullname: L Ruo – volume: 102 start-page: 1327 year: 2010 ident: 2132_CR11 publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605651 contributor: fullname: G Peach – volume: 99 start-page: 1285 year: 2008 ident: 2132_CR39 publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6604664 contributor: fullname: D Horst – volume: 138 start-page: 1714 year: 2010 ident: 2132_CR10 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2010.01.008 contributor: fullname: NN Rahbari – volume-title: Modelling survival data year: 2000 ident: 2132_CR21 contributor: fullname: TM Grambsch – volume: 1210 start-page: 66 year: 2010 ident: 2132_CR31 publication-title: Ann N Y Acad Sci. doi: 10.1111/j.1749-6632.2010.05779.x contributor: fullname: S Riethdorf – volume: 22 start-page: 364 year: 2010 ident: 2132_CR3 publication-title: Curr Opin Oncol. doi: 10.1097/CCO.0b013e32833a6c8a contributor: fullname: N Kemeny – volume: 230 start-page: 309 year: 1999 ident: 2132_CR17 publication-title: Ann Surg. doi: 10.1097/00000658-199909000-00004 contributor: fullname: Y Fong – volume: 8 start-page: 90 year: 2011 ident: 2132_CR34 publication-title: Nat Rev Gastroenterol Hepatol. doi: 10.1038/nrgastro.2010.211 contributor: fullname: SS Zeki – volume: 12 start-page: 130 year: 2006 ident: 2132_CR15 publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2006.01.006 contributor: fullname: S Mocellin – volume: 102 start-page: 1313 year: 2010 ident: 2132_CR1 publication-title: Br J Cancer. doi: 10.1038/sj.bjc.6605659 contributor: fullname: JN Primrose – volume: 11 start-page: 327 year: 2005 ident: 2132_CR9 publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2005.05.002 contributor: fullname: S Mocellin – ident: 2132_CR26 – volume: 12 start-page: 4605 year: 2006 ident: 2132_CR16 publication-title: Clin Cancer Res. doi: 10.1158/1078-0432.CCR-06-0823 contributor: fullname: S Mocellin – volume: 9 start-page: 489 year: 2009 ident: 2132_CR27 publication-title: Nat Rev Cancer. doi: 10.1038/nrc2645 contributor: fullname: A Walther – volume: 118 start-page: 2111 year: 2008 ident: 2132_CR36 publication-title: J Clin Invest. contributor: fullname: SV Shmelkov – volume: 25 start-page: 402 year: 2001 ident: 2132_CR20 publication-title: Methods. doi: 10.1006/meth.2001.1262 contributor: fullname: KJ Livak – volume: 28 start-page: 2300 year: 2010 ident: 2132_CR5 publication-title: J Clin Oncol. doi: 10.1200/JCO.2009.26.9340 contributor: fullname: DG Power – volume: 3 start-page: 131 year: 2009 ident: 2132_CR4 publication-title: Expert Rev Gastroenterol Hepatol. doi: 10.1586/egh.09.8 contributor: fullname: SC Mayo – volume: 78 start-page: 309 year: 2011 ident: 2132_CR37 publication-title: Oncology. doi: 10.1159/000318862 contributor: fullname: K Nakamura – volume: 111 start-page: 741 year: 2004 ident: 2132_CR19 publication-title: Int J Cancer. doi: 10.1002/ijc.20347 contributor: fullname: S Mocellin – volume: 35 start-page: 668 year: 2009 ident: 2132_CR25 publication-title: Cancer Treat Rev. doi: 10.1016/j.ctrv.2009.08.005 contributor: fullname: M Hebbar – volume: 110 start-page: 534 year: 2007 ident: 2132_CR42 publication-title: Cancer. doi: 10.1002/cncr.22774 contributor: fullname: EH Lin – volume: 46 start-page: 642 year: 2011 ident: 2132_CR38 publication-title: Eur J Cancer. doi: 10.1016/j.ejca.2009.11.003 contributor: fullname: R Artells – volume: 14 start-page: 2073 year: 2011 ident: 2132_CR41 publication-title: J Cell Mol Med. doi: 10.1111/j.1582-4934.2010.01117.x contributor: fullname: P Gazzaniga – volume: 192 start-page: 373 year: 2010 ident: 2132_CR29 publication-title: J Cell Biol. doi: 10.1083/jcb.201010021 contributor: fullname: M Yu – ident: 2132_CR6 doi: 10.1002/14651858.CD003770.pub3 – volume: 359 start-page: 1309 issue: 9314 year: 2002 ident: 2132_CR23 publication-title: Lancet doi: 10.1016/S0140-6736(02)08272-7 contributor: fullname: TG Clark – ident: 2132_CR30 doi: 10.1371/journal.pone.0012517 – volume: 10 start-page: 3042 year: 2005 ident: 2132_CR2 publication-title: Front Biosci. doi: 10.2741/1761 contributor: fullname: M Lise – volume: 26 start-page: 3057 year: 2007 ident: 2132_CR24 publication-title: Stat Med. doi: 10.1002/sim.2787 contributor: fullname: O Harel – volume: 138 start-page: 2151 year: 2011 ident: 2132_CR35 publication-title: Gastroenterology. doi: 10.1053/j.gastro.2009.12.063 contributor: fullname: M Todaro – volume: 14 start-page: 1070 year: 2009 ident: 2132_CR14 publication-title: Oncologist. doi: 10.1634/theoncologist.2009-0094 contributor: fullname: E Dotan – volume: 17 start-page: 343 year: 1996 ident: 2132_CR22 publication-title: Control Clin Trials. doi: 10.1016/0197-2456(96)00075-X contributor: fullname: M Schemper – volume: 7 start-page: 111 year: 2009 ident: 2132_CR18 publication-title: J Transl Med doi: 10.1186/1479-5876-7-111 contributor: fullname: L Bertazza – volume: 445 start-page: 111 issue: 7123 year: 2007 ident: 2132_CR32 publication-title: Nature doi: 10.1038/nature05384 contributor: fullname: L Ricci-Vitiani – volume: 9 start-page: 13 year: 2010 ident: 2132_CR8 publication-title: J Natl Compr Canc Netw. doi: 10.6004/jnccn.2011.0004 contributor: fullname: RK Kelley – volume: 16 start-page: 398 year: 2010 ident: 2132_CR13 publication-title: Trends Mol Med. doi: 10.1016/j.molmed.2010.07.001 contributor: fullname: K Pantel |
SSID | ssj0017305 |
Score | 2.3725257 |
Snippet | Background
Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease.... Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We tested... Background: Although surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease.... BACKGROUNDAlthough surgery is the gold standard treatment of hepatic metastasis from colorectal cancer (CRC), many patients ultimately die of their disease. We... |
SourceID | proquest crossref pubmed springer |
SourceType | Aggregation Database Index Database Publisher |
StartPage | 402 |
SubjectTerms | Aged Biomarkers, Tumor - genetics Biomarkers, Tumor - metabolism Colorectal Cancer Colorectal Neoplasms - mortality Colorectal Neoplasms - pathology Colorectal Neoplasms - surgery Female Follow-Up Studies Hepatectomy Humans Liver Neoplasms - mortality Liver Neoplasms - secondary Liver Neoplasms - surgery Lymphatic Metastasis Male Medicine Medicine & Public Health Middle Aged Neoplasm Recurrence, Local - diagnosis Neoplasm Recurrence, Local - mortality Neoplasm Recurrence, Local - surgery Neoplasm Staging Neoplastic Cells, Circulating - metabolism Neoplastic Cells, Circulating - pathology Neoplastic Stem Cells - metabolism Neoplastic Stem Cells - pathology Oncology Prognosis Real-Time Polymerase Chain Reaction Retrospective Studies Reverse Transcriptase Polymerase Chain Reaction Surgery Surgical Oncology Survival Rate |
Title | Prognostic Value of Putative Circulating Cancer Stem Cells in Patients Undergoing Hepatic Resection for Colorectal Liver Metastasis |
URI | https://link.springer.com/article/10.1245/s10434-011-2132-2 https://www.ncbi.nlm.nih.gov/pubmed/22071867 https://www.proquest.com/docview/917318165 https://search.proquest.com/docview/1746879976 https://search.proquest.com/docview/917858406 |
Volume | 19 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB6VVkJcCuXRhtLKSD2BjBLbSexjFbZaoK1WakHcLK9jVyuWBG2SX8AfZ5xkt0Klh3L2yBmNx-NvMi-AE8FyI1IZU5WXngplLDUIzKm03OTMC6lcqHeeXuWX3-XHSWiTwza_LqofH9YRyd5Q9w0QRBpq3QQPCRMJZehBUTS7O_j0pKjbO6eTz9PzTewAdTbtY5wZXmWWpWMs85-b_P0a3YGYd8Kj_atz9vR_-H0GuyPGJKeDUuzBlquew-OLMYr-An7PVnXIr8Nl8s0sO0dqT2Zd2_cAJ8ViZfuZXtUNKYJOrMhV636Swi2XDVlUZDa0Ym1IPzPppg6EUxcysy0JiXx9pQRBMEwKtKzBoiIz5yH_g1y41iAcbRbNS_h6NrkupnQcxkAtetAt5VbFIR1WZnOPsENY6XM1jz03zs5V7CxPvRGl5KUtORcitYmTJuFzaUQeBi6-gu2qrtwBkNKy2JbCe6GQ0DsEgUq4jLs4dtInNoJ360PRv4aeGzr4KihWPYhVo1h1EKtmERyuj02P16_R6IOirUqyNIK3m1W8NyEYYipXd41GTyyTuUI0FgG5hwa3kQjQYiTZHxRiww9jiM1klkfwfn38t5-_l9nXD6I-hCcIz9iQI_4GtttV547gUVN2x6POH6MT8OnLH4Gj--g |
link.rule.ids | 315,782,786,27933,27934,41073,42142,48344,48347,48357,49649,49652,49662,52153 |
linkProvider | Springer Nature |
linkToHtml | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9QwEB7BVgIuvKGhBYzECRQpsZ3EPkLa1VbsrlZqQdwsr2NXKy1JtUl-AX-ccR6LqtJDOXuUjMYz4280L4CPnGaaJyIKZVa4kEttQo3APBSG6Yw6LqT1_c6z82z5U5yc-jE5bOyF6ardx5Rk56m7CQg88c1unPmKiTikGEKF6HcPOIJ1OoGD6dny62qfPEClTbokZ4q2TNNkSGb-8yPXn6MbGPNGfrR7dqZP_ovhp_B4QJnkS68Wz-CeLZ_Dg8WQR38Bv1e7ylfY4TH5obetJZUjq7bppoCTfLMz3Vav8pLkXit25Lyxv0hut9uabEqy6oex1qTbmnRZecKZ9bXZhvhSvq5XgiAcJjn6Vu9TkZm5rwAhC9toBKT1pn4J36enF_ksHNYxhAZj6CZkRka-IFaka4fAgxvhMrmOHNPWrGVkDUuc5oVghSkY4zwxsRU6ZmuheeZXLr6CSVmV9hBIYWhkCu4cl0joLMJAyW3KbBRZ4WITwKfxVtRVP3VD-WgFxap6sSoUq_JiVTSAo_He1GCAtcIoFL1VnCYBfNifouX4dIgubdXWCmOxVGQS8VgA5BYa_IxAiBYhyeteI_b8UIroTKRZAJ_H6__7-1uZfXMn6vfwcHaxmKv52fLbETxCsEb7ivFjmDS71r6F-3XRvhsM4A-rvv7i |
linkToPdf | http://sdu.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1Lb9QwEB5BK1VceNOGUjASJ1BEYjuJfUKQdrUV7SpSAXGzvI5drbRNqk3yC_jjjPNYhNoeEGePktF4ZvyN5gXwjtNM80REocxKF3KpTagRmIfCMJ1Rx4W0vt95fpEtforjEz8m59PUC9NXu08pyaGnwU9pqtqP16UbpiHwxDe-cearJ-KQYjgVog_e5YglMPranZ0uvhTbRAIqcNInPFO0a5omY2Lz1o_8_TTdwJs3cqX9EzR79N_MP4aHI_oknwd1eQL3bPUU9s7H_Poz-FVsal95h8fkh153ltSOFF3bTwcn-Wpj-m1f1SXJvbZsyEVrr0hu1-uGrCpSDENaG9JvU7qsPeHc-pptQ3yJX99DQRAmkxx9rve1yMyZrwwh57bVCFSbVfMcvs9OvuXzcFzTEBqMrduQGRn5QlmRLh0CEm6Ey-Qyckxbs5SRNSxxmpeClaZkjPPExFbomC2F5plfxfgCdqq6sgdASkMjU3LnuERCZ_FKJbcps1FkhYtNAO-nG1LXwzQO5aMYFKsaxKpQrMqLVdEADqc7VKNhNgqjU_RicZoE8HZ7ihbl0yS6snXXKIzRUpFJxGkBkDto8DMCoVuEJPuDdmz5oRRRm0izAD5MqvDn93cy-_KfqN_AXnE8U2eni6-H8AAxHB0KyV_BTrvp7BHcb8ru9WgLvwEoHAfT |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Prognostic+Value+of+Putative+Circulating+Cancer+Stem+Cells+in+Patients+Undergoing+Hepatic+Resection+for+Colorectal+Liver+Metastasis&rft.jtitle=Annals+of+surgical+oncology&rft.au=Pilati%2C+Pierluigi&rft.au=Mocellin%2C+Simone&rft.au=Bertazza%2C+Loris&rft.au=Galdi%2C+Francesca&rft.date=2012-02-01&rft.pub=Springer-Verlag&rft.issn=1068-9265&rft.eissn=1534-4681&rft.volume=19&rft.issue=2&rft.spage=402&rft.epage=408&rft_id=info:doi/10.1245%2Fs10434-011-2132-2&rft.externalDocID=10_1245_s10434_011_2132_2 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1068-9265&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1068-9265&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1068-9265&client=summon |